Pharmacoepidemiologist Denise Boudreau, PhD, joined Kaiser Permanente Washington Health Research Institute (KPWHRI) in 2003. Since then, she has played an integral role in investigations into the safety and effectiveness of pharmaceuticals. Highly regarded for her expertise in pharmacoepidemiologic methods, Dr. Boudreau has diverse experiences in the subject that span pharmacies, classrooms, and research institutions.
Dr. Boudreau uses “big data” to conduct research in real-world settings. She brings an in-depth working knowledge of Kaiser Permanente Washington pharmacy data and practices to her research, which ranges from cancer to opioid medication safety to treating opioid use disorder. She has been the Health Care Systems Research Network Steering Committee Representative for the U.S. Food and Drug Administration (FDA) Sentinel Initiative for the past 10 years and was extensively involved in developing both the data and methods for signal detection of adverse drug events. She is currently serving a 4-year term on the FDA Drug Safety and Risk Management Advisory Committee.
Dr. Boudreau has pioneered work in the field of medication safety relating to cancer risk and cancer outcomes, as well as medication management of comorbidities among cancer survivors. For the last 5 years, she has dedicated her research to helping find solutions the opioid epidemic and improve treatment of opioid use disorder in the United States. She is currently leading two large multisite studies on the risk of misuse, abuse, and addiction with long-term opioid therapy, and the risk of birth defects with opioid use during pregnancy. Dr. Boudreau is a co-investigator on a clinical trial to improve treatment of opioid use disorder. She is site principal investigator of a trial to test the effectiveness of pain self-management training with optional supported opioid taper among chronic high-dose opioid users.
Dr. Boudreau's research has been exhibited internationally at conferences such as the International Society for Pharmacoepidemiology, the International Society for Pharmacoeconomics and Outcomes Research, and the Congress of Epidemiology. Her professional memberships include the International Society for Pharmacoepidemiology.
Dr. Boudreau worked as a pharmacist before earning her master’s degree in pharmacy administration (1996) from the University of Rhode Island and PhD from the Pharmaceutical Outcomes and Research Policy Program (2002) at the University of Washington (UW). Dr. Boudreau is an affiliate professor in the UW School of Pharmacy and UW Department of Epidemiology where she teaches the graduate pharmacoepidemiology course and mentors students. She retains her pharmacy license in Washington state.
General drug safety research; pharmacoepidemiology; observational study research methods; active surveillance on the safety of pharmaceuticals; validation of pharmacy data sources; pharmacy practice research; benefits and risks of opioids; treatment of opioid use disorder; and clinical and biologic effect of commonly used medications on cancer risk and outcomes
Prevention and treatment
Sullivan M, Boudreau DM, Ichikawa L, Cronkite D, Alberson-Junkans L, Salgado G, VonKorff M, Carrell DS. Primary care opioid taper plans are associated with sustained opioid dose reduction. J Gen Intern Med. 2020 Jan 6. doi: 10.1007/s11606-019-05445-1. [Epub ahead of print]. PubMed
Gold HT, Shao H, Oratz R, Yu O, Hammer M, Richardson SB, Boudreau DM. Association of diabetes and other clinical and sociodemographic factors with guideline-concordant breast cancer treatment for breast cancer. Am J Clin Oncol. 2019 Dec 16. doi: 10.1097/COC.0000000000000638. [Epub ahead of print]. PubMed
Lapham GT, Boudreau DM, Johnson EA, Bobb JF, Matthews AG, McCormack JF, Liu D, Samet JH, Saxon AJ, Campbell CI, Glass JE, Rossom RC, Murphy MT, Binswanger IA, Yarborough BH, PROUD Collaborative Authors, Bradley KA. Prevalence and treatment of opioid use disorder among primary care patients in six health systems. Drug Alcohol Depend. 2019 Nov 15;207:107732. doi: 10.1016/j.drugalcdep.2019.107732. [Epub ahead of print]. PubMed
Chen L, Chubak J, Yu O, Pocobelli G, Ziebell RA, Aiello Bowles EJ, Fujii MM, Sterrett AT, Boggs JM, Burnett-Hartman AN, Ritzwoller DP, Hubbard RA, Boudreau DM. Changes in use of opioid therapy after colon cancer diagnosis: a population-based study. Cancer Causes Control. Oct 30. doi: 10.1007/s10552-019-01236-5. [Epub ahead of print]. PubMed
Cook AJ, Wellman RD, Marsh T, Shoaibi A, Tiwari R, Nguyen M, Boudreau D, Weintraub ES, Jackson L, Nelson JC. Applying sequential surveillance methods that use regression adjustment or weighting to control confounding in a multi-site, rare event, distributed setting: part 2:in-depth example of a re-analysis of the measles-mumps-rubella-varicella combination vacc J Clin Epidemiol. 2019 Sep; 113:114-122. PubMed
Tom Petty’s accidental death from opioids shows we need to find safer alternatives for chronic pain. See how KPWHRI research helps to do just that.
Researchers find a relationship between prescribed central nervous system-active medications and increased risk of falling among older people with dementia.
Risk-reduction initiative for chronic opioid therapy sustains patient-doctor trust, Dr. Karen Sherman finds.
Dr. David Arterburn discusses reassuring news from his PCORnet study of the most widely used anti-obesity drug in the United States.